In addition to our HBV pipeline, we are actively licensing our Lipid Nanoparticle (LNP) technology to our industry partners. Our LNP technology represents a proven delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects. We continue to explore opportunities to generate value from our LNP platform technology, which is well suited to deliver therapies based on RNAi, mRNA, and gene editing constructs. We see significant value in the collaborations Arbutus has established to date, and will continue to work closely with, and support, our partners using our LNP technology.
Our management team has significant experience in discovering and developing drug candidates targeting infectious liver diseases, including HCV. We are applying to our HBV programs, the same innovative thinking that members of our management team have successfully applied to developing a cure for HCV. We are dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, and to maximizing the value of our LNP technology.